Michael Barbella, Managing Editor07.19.23
Pulvinar Neuro, a wholly owned subsidiary of Electromedical Products International Inc. (EPI), has been awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.
The three-year, $3.06 million Phase II SBIR grant from the NIH’s National Institute of Mental Health (NIMH) will be used to develop a cloud-enabled TCS device that delivers personalized closed-loop brain stimulation for clinical and at-home applications. The grant also includes funding for a double-blind, placebo-controlled study of the cloud-enabled TCS device in 30 patients with major depressive disorder.
"This NIH grant will enable us to take a key step forward in the development of our novel brain stimulation treatment for mental illness," EPI Chief Science Officer Leah Townsend, Ph.D., said. “We are grateful to NIMH for supporting our work developing this important, innovative technology.”
EPI is a medical device company developing non-invasive brain stimulation technology for psychiatric disorders and pain management. EPI manufactures the Alpha-Stim brand of patented devices that are U.S. Food and Drug Administration-cleared to provide fast, safe, and effective treatment of anxiety and insomnia via cranial electrotherapy stimulation (CES) and pain via microcurrent electrical therapy (MET). Alpha-Stim is available in more than 50 countries worldwide and is available via prescription in the United States.
Pulvinar Neuro is a neurotechnology company dedicated to supporting the research community with non-invasive brain stimulation research tools as well as the technical development of innovative therapeutics to address mental health challenges.
The three-year, $3.06 million Phase II SBIR grant from the NIH’s National Institute of Mental Health (NIMH) will be used to develop a cloud-enabled TCS device that delivers personalized closed-loop brain stimulation for clinical and at-home applications. The grant also includes funding for a double-blind, placebo-controlled study of the cloud-enabled TCS device in 30 patients with major depressive disorder.
"This NIH grant will enable us to take a key step forward in the development of our novel brain stimulation treatment for mental illness," EPI Chief Science Officer Leah Townsend, Ph.D., said. “We are grateful to NIMH for supporting our work developing this important, innovative technology.”
EPI is a medical device company developing non-invasive brain stimulation technology for psychiatric disorders and pain management. EPI manufactures the Alpha-Stim brand of patented devices that are U.S. Food and Drug Administration-cleared to provide fast, safe, and effective treatment of anxiety and insomnia via cranial electrotherapy stimulation (CES) and pain via microcurrent electrical therapy (MET). Alpha-Stim is available in more than 50 countries worldwide and is available via prescription in the United States.
Pulvinar Neuro is a neurotechnology company dedicated to supporting the research community with non-invasive brain stimulation research tools as well as the technical development of innovative therapeutics to address mental health challenges.